Blood pressure treatment in small vessel disease

St George's University of London (UK)0 个研究点目标入组 422 人开始时间: 2012年1月25日最近更新: 2021年6月14日

适应症

试验速览

•1. Clinical evidence of cerebral small vessel disease with MRI evidence of lacunar infarcts(s) (<=1.5cm maximum diameter) and confluent leukoaraiosis (defined on Fazekas scale as >=grade 2)
•2. Clinical evidence of cerebral small vessel disease is defined as:
•a.Lacunar stroke syndrome with symptoms lasting >24 hours
•3. Transient ischaemic attack lasting < 24 hours with limb weakness, hemisensory loss or dysarthria AND with MR DWI imaging performed acutely showing lacunar infarction, or if MRI is not performed acutely (>2 weeks after TIA) with a lacunar infarction in an anatomically appropriate position on MRI
•4. Vascular cognitive impairment with MRI shoing no evidence of hippocampal atrophy
•5. Systolic BP > 140 mmHg
•6. Taking no more than two BP lowering drugs at assessed for study participation.
•7. Aged 40 years or over
•8. Not diagnosed with dementia and Minimental state examination (MMSE) 21
•9. Able and willing to consen
•10. Expected life expectancy > 2 years
•11. Able to perform study cognitive assessment

•1. Unable or unwilling to conset
•2. Women of childbearingage
•3. Minimental state examination (MMSE) <21 or diagnosis of dementia on Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria
•4. Life expectancy less than 2 years
•5. Symptomatic postural hypotension
•6. Known single gene disorder causing small vessel disease (eg CADASI)
•7. Cortical infarction (>2 cm maximum diamete)
•8. Symptomatic carotid stenosis or vertebral stenosis >70% as measured on NASCET criteria

发起方

St George's University of London (UK)